Strides Pharma Science Ltd - 532531 - Proceedings Of The Extraordinary General Meeting (EGM) Of The Company
We wish to inform you that the EGM of the Company was held on Thursday, April 7, 2022 through Video Conference. Pursuant to Regulation 30, Part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed the summary of proceedings of the EGM. This is for your information and records. Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Change in Directorate
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Resignation of Managing Director
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides announces Leadership changes Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 28, 2022 for Pronomz Ventures LLP Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding request received for Loss of Share Certificates under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 24, 2022 for Pronomz Ventures LLP
Strides Pharma Science inks pact with MPP to market COVID-19 drug
The Pfizer product has been authorised as a COVID-19 oral therapy for emergency use in the US and other countries for high-risk adults and pediatric patients. Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides partners with Medicines Patent Pool (MPP) to commercialize the generic version of Pfizer's COVID-19 Oral Treatment across 95 markets
Biolexis to collaborate with Akston Biosciences for Covid-19 vaccine
Biolexis, a division of Stelis Biopharma, and Akston Biosciences have inked a licensing, manufacturing and commercialisation agreement regarding a COVID-19 vaccine. In a joint statement, the two companies said they will collaborate for the production and sales of Akston's AKS-452, a protein subunit COVID-19 vaccine. Under the agreement, Biolexis gained the right to manufacture and commercialise AKS-452 (branded as AmbiVax-CTM) in India and over 130 countries in Asia, Latin America, and Africa, largely covering the low-and middle-income countries (LMICs). Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships. Last year, the board of Strides Pharma Science had approved the demerger of its biotech business under Stelis Biopharma. "We are very excited to partner with Akston on AmbiVax-CTM, which is a first-of-its-kind COVID-19 vaccine developed for all parts of th